Co-Diagnostics, Inc.: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 14, 2018 and accepted by EDGAR at May 14, 2018, 17:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Gross profit | 3 months2018-01-01 to 2018-03-31 | $9.7k | us-gaap:GrossProfit |
| Research and development | 3 months2018-01-01 to 2018-03-31 | $297.4k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-01-01 to 2018-03-31 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-01-01 to 2018-03-31 | $141.4k | us-gaap:InterestExpense |
| Net income | 3 months2018-01-01 to 2018-03-31 | −$1.3m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2018-01-01 to 2018-03-31 | −$968.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2018-01-01 to 2018-03-31 | $9.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-03-31 | $2.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-03-31 | $3.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $3.3m | us-gaap:Assets |
| Current liabilities | At period end2018-03-31 | $286.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-03-31 | $761.8k | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-03-31 | $2.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-18-006835. Last ingested by Listed: Nov 4, 2026, 18:23 ET. Listed shows no prices and gives no investment advice.